Product nameAnti-C3 / C3a antibody 
See all C3 / C3a primary antibodies
DescriptionMouse monoclonal  to C3 / C3a
SpecificityThe antibody reacts with an epitope on C3a. It reacts with both intact C3, as with C3a. See references, multiple isoforms of this protein exist (multiple bands may appears in WB).
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Unfortunately, this information is considered to be commercially sensitive
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.02% Sodium azide
Constituents: PBS, 0.1% BSA
Concentration information loading...
PurityProtein G purified
Our Abpromise guarantee covers the use of ab11872 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use at an assay dependent dilution. Predicted molecular weight: 187.2 kDa.|
FunctionC3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils (By similarity). It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
C3-beta-c: Acts as a chemoattractant for neutrophils in chronic inflammation.
Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (PubMed:8376604, PubMed:2909530, PubMed:9059512, PubMed:10432298, PubMed:15833747, PubMed:16333141, PubMed:19615750).
Tissue specificityPlasma. The acylation stimulating protein (ASP) is expressed in adipocytes and released into the plasma during both the fasting and postprandial periods.
Involvement in diseaseComplement component 3 deficiency
Macular degeneration, age-related, 9
Hemolytic uremic syndrome atypical 5
Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage.
Sequence similaritiesContains 1 anaphylatoxin-like domain.
Contains 1 NTR domain.
modificationsC3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g. C3a is further processed by carboxypeptidases to release the C-terminal arginine residue generating the acylation stimulating protein (ASP). Levels of ASP are increased in adipocytes in the postprandial period and by insulin and dietary chylomicrons.
Phosphorylated by FAM20C in the extracellular medium.
- Information by UniProt
- Acylation stimulating protein antibody
- AHUS5 antibody
- ARMD9 antibody
Lanes 1 & 4 : Anti-C3 / C3a antibody  (ab11872) at 1/250 dilution (in 2% BSA for 3 hours at 4°C)
Lanes 2 & 5 : Anti-C3 / C3a antibody  (ab11872) at 1/500 dilution (in 2% BSA for 3 hours at 4°C)
Lanes 3 & 6 : Anti-C3 / C3a antibody  (ab11872) at 1/1000 dilution (in 2% BSA for 3 hours at 4°C)
All lanes : Human serum
Lysates/proteins at 20 µg per lane.
All lanes : An HRP-conjugated Sheep anti-mouse polyclonal at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 187.2 kDa
Exposure time: 5 minutes
Lanes 1-3:- 5% Skimmed Milk; Lanes 4-6:- 2% BSA
This product has been referenced in:
- Shi L et al. Discovery and identification of potential biomarkers of pediatric Acute Lymphoblastic Leukemia. Proteome Sci 7:7 (2009). Read more (PubMed: 19291297) »
- Li RX et al. Localized-statistical quantification of human serum proteome associated with type 2 diabetes. PLoS ONE 3:e3224 (2008). WB ; Human . Read more (PubMed: 18795103) »